1. PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS' ERA. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 2132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗